Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NZ MenB OMV vaccine
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The NZ MenB OMV vaccine (MeNZB) is an outer membrane vesicle (OMV) vaccine developed specifically to control an epidemic of invasive disease caused by Neisseria meningitidis serogroup B in New Zealand. The active component consists of outer membrane vesicles derived from the epidemic strain N. meningitidis group B subtype P1.7b,4 (strain NZ98/254). The primary mechanism is immunostimulation—inducing bactericidal antibodies against the PorA protein and other surface antigens present in the OMVs. Clinical studies demonstrated that a three-dose regimen was well tolerated and highly immunogenic across age groups[8]. This monovalent OMV-based formulation differs from later multicomponent vaccines like 4CMenB/Bexsero by lacking recombinant protein antigens.
- Brand names
- MeNZB
- Other names
- Meningococcal vaccine group B OMV (NZ)NZ MenB OMVNew Zealand epidemic strain meningococcal B outer membrane vesicle vaccine
02
Targets
PorA
Beyond the preview
Go deeper on NZ MenB OMV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NZ MenB OMV vaccine.